SAN DIEGO, Dec. 18, 2006 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the initiation of the Phase II clinical program to determine the safety and efficacy of MN-221, its novel intravenous product candidate for status asthmaticus. Status asthmaticus is an acute, long-lasting and severe asthma episode that does not respond to initial standard treatments and is potentially fatal.
